Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study was to evaluate the effect of the consumption of yogurt added with bifidobacteria and soluble fiber on gastrointestinal function of healthy adults. A product as herein described is expected to improve gastrointestinal function and maintain the intestinal microflora balance of healthy subjects and perhaps of patients with altered bowel functions.
| Condition | Intervention | Phase |
|---|---|---|
|
Inflammatory Bowel Diseases |
Other: yogurt added with bifidobacteria and soluble fiber (YBF) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function: A Randomized, Double-blind, Longitudinal Controlled Study in Mexican Adult. |
- Stools Frequency [ Time Frame: 0, 1, 2, 3, 4, 5 weeks ] [ Designated as safety issue: No ]Stools frequency was reported daily as follows: 0: zero 1= once, 2= twice, 3=three times, 4= four or more times
- Consistency of stools [ Time Frame: 0, 1, 2, 3, 4, 5 weeks ] [ Designated as safety issue: No ]Consistency of stools was scored according to the following scale: 1= watery and liquid, 2= soft and unformed, 3= soft and formed, and 4= hard and dry.
- Difficulty of defecation [ Time Frame: 0,1,2,3,4,5 ] [ Designated as safety issue: No ]Difficulty of defecation was evaluated as 1= very easy, 2= easy, 3= hard, 4= very hard.
- Abdominal distension [ Time Frame: 0,1,2,3,4,5 ] [ Designated as safety issue: Yes ]Abdominal distension was evaluated as 1= no symptoms, 2= slight symptoms that did not influence daily activities, 3= moderate symptoms that could influence daily activities, 4= severe symptoms that affected daily activities.
- Flatulence [ Time Frame: 0,1,2,3,4,5 ] [ Designated as safety issue: Yes ]Flatulence was evaluated as 1= no symptoms, 2= slight symptoms that did not influence daily activities, 3= moderate symptoms that could influence daily activities, 4= severe symptoms that affected daily activities.
- Abdominal pain [ Time Frame: 0,1,2,3,4,5 weeks ] [ Designated as safety issue: Yes ]Abdominal pain was evaluated as 1= no symptoms, 2= slight symptoms that did not influence daily activities, 3= moderate symptoms that could influence daily activities, 4= severe symptoms that affected daily activities.
| Enrollment: | 174 |
| Study Start Date: | June 2007 |
| Study Completion Date: | February 2008 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Yogurt+fiber+probiotic
Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
|
Other: yogurt added with bifidobacteria and soluble fiber (YBF)
Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
Other Names:
|
|
Placebo Comparator: regular yogurt
yogurt YR had no additional fiber or bifidobacterium
|
Other: yogurt added with bifidobacteria and soluble fiber (YBF)
Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
Other Names:
|
Detailed Description:
The use of probiotics and prebiotics has become popular in human nutrition and food product development. The most common probiotics are Lactobacillus and Bifidobacterium species. Bifidobacteria spp are dominant in the intestinal microflora and are considered to be beneficial to the host, for this reason research efforts have focused on increasing their proportion in the intestinal microflora through oral administration of mixtures containing bifidobacteria or oral supplementation with prebiotics. An important limitation for the effectiveness of oral probiotics is that they might be destroyed during digestion in the gastrointestinal tract therefore and adequate vehicle could improve its potential benefits. Yogurt is a suitable vehicle for the administration of bifidobacteria, due to its physicochemical properties, such as pH and nutrients content, as well as the organoleptic properties that contribute to its increasing consumption. Thus simultaneous administration of probiotics and prebiotics in a suitable vehicle could act synergistically and may have potential for improving gut health. Few clinical trials have been performed using prebiotics and probiotics. The aim of this study was to evaluate the effect of the consumption of yogurt added with bifidobacteria and soluble fiber on gastrointestinal function of healthy adults. A product as herein described is expected to improve gastrointestinal function and maintain the intestinal microflora balance of healthy subjects and perhaps of patients with altered bowel functions.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age between 18 and 55 years,
- be free of known gastrointestinal diseases,
- desist of consuming prebiotic and/or probiotic-containing foods or dietary supplements during the entire duration of the study,
- agree to avoid any medication that produced changes in gastrointestinal function, diarrhea or constipation until completion of the study,
- be willing to complete all necessary study questionnaires,
- accept voluntary participation and sign a written informed consent before inclusion in the study.
Exclusion Criteria:
- subjects receiving any kind of treatment that may had altered bowel function;
- intake of laxatives,
- a concomitant sever gastrointestinal disease;
- that were consuming probiotics and/or prebiotics-containing foods or dietary supplements within the two previous weeks;
- subjects were also excluded if they had received any antimicrobial medication during the previous 2 months.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Jorge Luis Rosado Loría, Universidad autonoma de queretaro |
| ClinicalTrials.gov Identifier: | NCT01173588 History of Changes |
| Other Study ID Numbers: | PEE-001-2007 |
| Study First Received: | July 29, 2010 |
| Last Updated: | July 29, 2010 |
| Health Authority: | Mexico: Ethics Committee |
Keywords provided by Instituto Lala:
|
bowel function functional foods |
Additional relevant MeSH terms:
|
Inflammatory Bowel Diseases Intestinal Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013